RESULTS
Eighty patients underwent tandem AHCT on ANBL0532 and had MIBG scans obtained at both diagnosis and end-induction. Demographics and disease characteristics for these 80 patients are shown in TABLE 1 . Fifty-six tandem AHCT recipients (70%) subsequently received immunotherapy with dinutuximab and cytokines, either on ANBL0032 (n=50) or ANBL0931 (n=6). Patients who did not receive immunotherapy either did not enroll on ANBL0032 or ANBL0931, or were enrolled on ANBL0032 but were not randomized to receive immunotherapy. Patient and disease characteristics for the subset of patients that underwent tandem AHCT (n=80) in our CS analysis were consistent with those of the larger cohort of patients (n=355) randomized on ANBL0532 (Supplemental TABLE S1) .3